APO Research
Talk to an analyst

APO RESEARCH · REPORT

Islet Amyloid Polypeptide

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Islet Amyloid Polypeptide Market Outlook and Growth Opportunities 2026

19 December 2025194 pages

Choose your research edition.

Industry ResearchIslet Amyloid Polypeptide Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Islet Amyloid Polypeptide Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Islet Amyloid Polypeptide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Islet Amyloid Polypeptide Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Islet Amyloid Polypeptide Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Islet Amyloid Polypeptide market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Islet Amyloid Polypeptide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Islet Amyloid Polypeptide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Islet Amyloid Polypeptide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Islet Amyloid Polypeptide market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Islet Amyloid Polypeptide market include Adocia SAS, Neurimmune Holding AG, Nordic Bioscience A/S, Prothena Corp Plc, reMYND NV, Zealand Pharma AS, AstraZeneca Plc and Eli Lilly and Co, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Islet Amyloid Polypeptide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Islet Amyloid Polypeptide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Islet Amyloid Polypeptide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Islet Amyloid Polypeptide market size, projected growth trends, production technologies, key applications, and end-use industries.

Islet Amyloid Polypeptide Segment by Company

Adocia SAS

Neurimmune Holding AG

Nordic Bioscience A/S

Prothena Corp Plc

reMYND NV

Zealand Pharma AS

AstraZeneca Plc

Eli Lilly and Co

Islet Amyloid Polypeptide Segment by Type

KBP-088

KBP-056

DACRA-089

DACRA-042

AC-253

Others

Islet Amyloid Polypeptide Segment by Application

Gastrointestinal

Musculoskeletal Disorders

Metabolic Disorders

Others

Islet Amyloid Polypeptide Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Islet Amyloid Polypeptide status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Islet Amyloid Polypeptide market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Islet Amyloid Polypeptide significant trends, drivers, influence factors in global and regions.

6. To analyze Islet Amyloid Polypeptide competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Islet Amyloid Polypeptide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Islet Amyloid Polypeptide and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Islet Amyloid Polypeptide.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Islet Amyloid Polypeptide market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Islet Amyloid Polypeptide industry.

Chapter 3: Detailed analysis of Islet Amyloid Polypeptide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Islet Amyloid Polypeptide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Islet Amyloid Polypeptide in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Islet Amyloid Polypeptide Industry Trends Table 2. Islet Amyloid Polypeptide Industry Drivers Table 3. Islet Amyloid Polypeptide Industry Opportunities and Challenges Table 4. Islet Amyloid Polypeptide Industry Restraints Table 5. Global Islet Amyloid Polypeptide Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Islet Amyloid Polypeptide Revenue Share by Company (2021-2026) Table 7. Global Islet Amyloid Polypeptide Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Islet Amyloid Polypeptide Sales Volume Share by Company (2021-2026) Table 9. Global Islet Amyloid Polypeptide Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Islet Amyloid Polypeptide Company Ranking, (2024-2026) & (USD Million) Table 11. Global Islet Amyloid Polypeptide Key Company Manufacturing Base & Headquarters Table 12. Global Islet Amyloid Polypeptide Company, Product Type & Application Table 13. Global Islet Amyloid Polypeptide Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Islet Amyloid Polypeptide by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of KBP-088 Table 18. Significant Companies of KBP-056 Table 19. Significant Companies of DACRA-089 Table 20. Significant Companies of DACRA-042 Table 21. Significant Companies of AC-253 Table 22. Significant Companies of Others Table 23. Global Islet Amyloid Polypeptide Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Islet Amyloid Polypeptide Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Islet Amyloid Polypeptide Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Islet Amyloid Polypeptide Sales Volume Share by Type (2021-2026) Table 27. Global Islet Amyloid Polypeptide Sales Volume Share by Type (2027-2032) Table 28. Global Islet Amyloid Polypeptide Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Islet Amyloid Polypeptide Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Islet Amyloid Polypeptide Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Islet Amyloid Polypeptide Sales Value Share by Type (2021-2026) Table 32. Global Islet Amyloid Polypeptide Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Gastrointestinal Table 34. Significant Companies of Musculoskeletal Disorders Table 35. Significant Companies of Metabolic Disorders Table 36. Significant Companies of Others Table 37. Global Islet Amyloid Polypeptide Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Islet Amyloid Polypeptide Sales Volume by Application (2021-2026) & (K Units) Table 39. Global Islet Amyloid Polypeptide Sales Volume by Application (2027-2032) & (K Units) Table 40. Global Islet Amyloid Polypeptide Sales Volume Share by Application (2021-2026) Table 41. Global Islet Amyloid Polypeptide Sales Volume Share by Application (2027-2032) Table 42. Global Islet Amyloid Polypeptide Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Islet Amyloid Polypeptide Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Islet Amyloid Polypeptide Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Islet Amyloid Polypeptide Sales Value Share by Application (2021-2026) Table 46. Global Islet Amyloid Polypeptide Sales Value Share by Application (2027-2032) Table 47. Global Islet Amyloid Polypeptide Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global Islet Amyloid Polypeptide Sales by Region (2021-2026) & (K Units) Table 49. Global Islet Amyloid Polypeptide Sales Market Share by Region (2021-2026) Table 50. Global Islet Amyloid Polypeptide Sales by Region (2027-2032) & (K Units) Table 51. Global Islet Amyloid Polypeptide Sales Market Share by Region (2027-2032) Table 52. Global Islet Amyloid Polypeptide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Islet Amyloid Polypeptide Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Islet Amyloid Polypeptide Sales Value Share by Region (2021-2026) Table 55. Global Islet Amyloid Polypeptide Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Islet Amyloid Polypeptide Sales Value Share by Region (2027-2032) Table 57. Global Islet Amyloid Polypeptide Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Islet Amyloid Polypeptide Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Islet Amyloid Polypeptide Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Global Islet Amyloid Polypeptide Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Islet Amyloid Polypeptide Sales by Country (2021-2026) & (K Units) Table 62. Global Islet Amyloid Polypeptide Sales Market Share by Country (2021-2026) Table 63. Global Islet Amyloid Polypeptide Sales by Country (2027-2032) & (K Units) Table 64. Global Islet Amyloid Polypeptide Sales Market Share by Country (2027-2032) Table 65. Global Islet Amyloid Polypeptide Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Islet Amyloid Polypeptide Sales Value Market Share by Country (2021-2026) Table 67. Global Islet Amyloid Polypeptide Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Islet Amyloid Polypeptide Sales Value Market Share by Country (2027-2032) Table 69. Adocia SAS Company Information Table 70. Adocia SAS Business Overview Table 71. Adocia SAS Islet Amyloid Polypeptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Adocia SAS Islet Amyloid Polypeptide Product Portfolio Table 73. Adocia SAS Recent Development Table 74. Neurimmune Holding AG Company Information Table 75. Neurimmune Holding AG Business Overview Table 76. Neurimmune Holding AG Islet Amyloid Polypeptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Neurimmune Holding AG Islet Amyloid Polypeptide Product Portfolio Table 78. Neurimmune Holding AG Recent Development Table 79. Nordic Bioscience A/S Company Information Table 80. Nordic Bioscience A/S Business Overview Table 81. Nordic Bioscience A/S Islet Amyloid Polypeptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Nordic Bioscience A/S Islet Amyloid Polypeptide Product Portfolio Table 83. Nordic Bioscience A/S Recent Development Table 84. Prothena Corp Plc Company Information Table 85. Prothena Corp Plc Business Overview Table 86. Prothena Corp Plc Islet Amyloid Polypeptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Prothena Corp Plc Islet Amyloid Polypeptide Product Portfolio Table 88. Prothena Corp Plc Recent Development Table 89. reMYND NV Company Information Table 90. reMYND NV Business Overview Table 91. reMYND NV Islet Amyloid Polypeptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. reMYND NV Islet Amyloid Polypeptide Product Portfolio Table 93. reMYND NV Recent Development Table 94. Zealand Pharma AS Company Information Table 95. Zealand Pharma AS Business Overview Table 96. Zealand Pharma AS Islet Amyloid Polypeptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Zealand Pharma AS Islet Amyloid Polypeptide Product Portfolio Table 98. Zealand Pharma AS Recent Development Table 99. AstraZeneca Plc Company Information Table 100. AstraZeneca Plc Business Overview Table 101. AstraZeneca Plc Islet Amyloid Polypeptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. AstraZeneca Plc Islet Amyloid Polypeptide Product Portfolio Table 103. AstraZeneca Plc Recent Development Table 104. Eli Lilly and Co Company Information Table 105. Eli Lilly and Co Business Overview Table 106. Eli Lilly and Co Islet Amyloid Polypeptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Eli Lilly and Co Islet Amyloid Polypeptide Product Portfolio Table 108. Eli Lilly and Co Recent Development Table 109. Key Raw Materials Table 110. Raw Materials Key Suppliers Table 111. Islet Amyloid Polypeptide Distributors List Table 112. Islet Amyloid Polypeptide Customers List Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Islet Amyloid Polypeptide Product Image Figure 2. Global Islet Amyloid Polypeptide Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Islet Amyloid Polypeptide Sales Value (2021-2032) & (US$ Million) Figure 4. Global Islet Amyloid Polypeptide Sales (2021-2032) & (K Units) Figure 5. Global Islet Amyloid Polypeptide Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Islet Amyloid Polypeptide Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. KBP-088 Image Figure 10. KBP-056 Image Figure 11. DACRA-089 Image Figure 12. DACRA-042 Image Figure 13. AC-253 Image Figure 14. Others Image Figure 15. Global Islet Amyloid Polypeptide Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Islet Amyloid Polypeptide Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Islet Amyloid Polypeptide Sales Volume Share by Type (2021-2032) Figure 18. Global Islet Amyloid Polypeptide Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Islet Amyloid Polypeptide Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Islet Amyloid Polypeptide Sales Value Share by Type (2021-2032) Figure 21. Gastrointestinal Image Figure 22. Musculoskeletal Disorders Image Figure 23. Metabolic Disorders Image Figure 24. Others Image Figure 25. Global Islet Amyloid Polypeptide Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Islet Amyloid Polypeptide Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Islet Amyloid Polypeptide Sales Volume Share by Application (2021-2032) Figure 28. Global Islet Amyloid Polypeptide Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Islet Amyloid Polypeptide Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Islet Amyloid Polypeptide Sales Value Share by Application (2021-2032) Figure 31. Global Islet Amyloid Polypeptide Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 32. Global Islet Amyloid Polypeptide Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Islet Amyloid Polypeptide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Islet Amyloid Polypeptide Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Islet Amyloid Polypeptide Sales Value (2021-2032) & (US$ Million) Figure 36. North America Islet Amyloid Polypeptide Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Islet Amyloid Polypeptide Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Islet Amyloid Polypeptide Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Islet Amyloid Polypeptide Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Islet Amyloid Polypeptide Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Islet Amyloid Polypeptide Sales Value (2021-2032) & (US$ Million) Figure 42. South America Islet Amyloid Polypeptide Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Islet Amyloid Polypeptide Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Islet Amyloid Polypeptide Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Islet Amyloid Polypeptide Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Islet Amyloid Polypeptide Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • KBP-088
  • KBP-056
  • DACRA-089
  • DACRA-042
  • AC-253
  • Others
Applications
  • Gastrointestinal
  • Musculoskeletal Disorders
  • Metabolic Disorders
  • Others
Companies covered
  • Adocia SAS
  • Neurimmune Holding AG
  • Nordic Bioscience A/S
  • Prothena Corp Plc
  • reMYND NV
  • Zealand Pharma AS
  • AstraZeneca Plc
  • Eli Lilly and Co

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Islet Amyloid Polypeptide Sales Value (2021-2032)
  4. 1.2.2 Global Islet Amyloid Polypeptide Sales Volume (2021-2032)
  5. 1.2.3 Global Islet Amyloid Polypeptide Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Islet Amyloid Polypeptide Market Dynamics
  1. 2.1 Islet Amyloid Polypeptide Industry Trends
  2. 2.2 Islet Amyloid Polypeptide Industry Drivers
  3. 2.3 Islet Amyloid Polypeptide Industry Opportunities and Challenges
  4. 2.4 Islet Amyloid Polypeptide Industry Restraints
3 Islet Amyloid Polypeptide Market by Company
  1. 3.1 Global Islet Amyloid Polypeptide Company Revenue Ranking in 2025
  2. 3.2 Global Islet Amyloid Polypeptide Revenue by Company (2021-2026)
  3. 3.3 Global Islet Amyloid Polypeptide Sales Volume by Company (2021-2026)
  4. 3.4 Global Islet Amyloid Polypeptide Average Price by Company (2021-2026)
  5. 3.5 Global Islet Amyloid Polypeptide Company Ranking (2024-2026)
  6. 3.6 Global Islet Amyloid Polypeptide Company Manufacturing Base and Headquarters
  7. 3.7 Global Islet Amyloid Polypeptide Company Product Type and Application
  8. 3.8 Global Islet Amyloid Polypeptide Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Islet Amyloid Polypeptide Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Islet Amyloid Polypeptide Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Islet Amyloid Polypeptide Market by Type
  1. 4.1 Islet Amyloid Polypeptide Type Introduction
  2. 4.1.1 KBP-088
  3. 4.1.2 KBP-056
  4. 4.1.3 DACRA-089
  5. 4.1.4 DACRA-042
  6. 4.1.5 AC-253
  7. 4.1.6 Others
  8. 4.2 Global Islet Amyloid Polypeptide Sales Volume by Type
  9. 4.2.1 Global Islet Amyloid Polypeptide Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Islet Amyloid Polypeptide Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Islet Amyloid Polypeptide Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Islet Amyloid Polypeptide Sales Value by Type
  13. 4.3.1 Global Islet Amyloid Polypeptide Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Islet Amyloid Polypeptide Sales Value by Type (2021-2032)
  15. 4.3.3 Global Islet Amyloid Polypeptide Sales Value Share by Type (2021-2032)
5 Islet Amyloid Polypeptide Market by Application
  1. 5.1 Islet Amyloid Polypeptide Application Introduction
  2. 5.1.1 Gastrointestinal
  3. 5.1.2 Musculoskeletal Disorders
  4. 5.1.3 Metabolic Disorders
  5. 5.1.4 Others
  6. 5.2 Global Islet Amyloid Polypeptide Sales Volume by Application
  7. 5.2.1 Global Islet Amyloid Polypeptide Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Islet Amyloid Polypeptide Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Islet Amyloid Polypeptide Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Islet Amyloid Polypeptide Sales Value by Application
  11. 5.3.1 Global Islet Amyloid Polypeptide Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Islet Amyloid Polypeptide Sales Value by Application (2021-2032)
  13. 5.3.3 Global Islet Amyloid Polypeptide Sales Value Share by Application (2021-2032)
6 Islet Amyloid Polypeptide Regional Sales and Value Analysis
  1. 6.1 Global Islet Amyloid Polypeptide Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Islet Amyloid Polypeptide Sales by Region (2021-2032)
  3. 6.2.1 Global Islet Amyloid Polypeptide Sales by Region: 2021-2026
  4. 6.2.2 Global Islet Amyloid Polypeptide Sales by Region (2027-2032)
  5. 6.3 Global Islet Amyloid Polypeptide Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Islet Amyloid Polypeptide Sales Value by Region (2021-2032)
  7. 6.4.1 Global Islet Amyloid Polypeptide Sales Value by Region: 2021-2026
  8. 6.4.2 Global Islet Amyloid Polypeptide Sales Value by Region (2027-2032)
  9. 6.5 Global Islet Amyloid Polypeptide Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Islet Amyloid Polypeptide Sales Value (2021-2032)
  12. 6.6.2 North America Islet Amyloid Polypeptide Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Islet Amyloid Polypeptide Sales Value (2021-2032)
  15. 6.7.2 Europe Islet Amyloid Polypeptide Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Islet Amyloid Polypeptide Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Islet Amyloid Polypeptide Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Islet Amyloid Polypeptide Sales Value (2021-2032)
  21. 6.9.2 South America Islet Amyloid Polypeptide Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Islet Amyloid Polypeptide Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Islet Amyloid Polypeptide Sales Value Share by Country, 2025 VS 2032
7 Islet Amyloid Polypeptide Country-level Sales and Value Analysis
  1. 7.1 Global Islet Amyloid Polypeptide Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Islet Amyloid Polypeptide Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Islet Amyloid Polypeptide Sales by Country (2021-2032)
  4. 7.3.1 Global Islet Amyloid Polypeptide Sales by Country (2021-2026)
  5. 7.3.2 Global Islet Amyloid Polypeptide Sales by Country (2027-2032)
  6. 7.4 Global Islet Amyloid Polypeptide Sales Value by Country (2021-2032)
  7. 7.4.1 Global Islet Amyloid Polypeptide Sales Value by Country (2021-2026)
  8. 7.4.2 Global Islet Amyloid Polypeptide Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Islet Amyloid Polypeptide Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Islet Amyloid Polypeptide Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Islet Amyloid Polypeptide Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Adocia SAS
  2. 8.1.1 Adocia SAS Company Information
  3. 8.1.2 Adocia SAS Business Overview
  4. 8.1.3 Adocia SAS Islet Amyloid Polypeptide Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Adocia SAS Islet Amyloid Polypeptide Product Portfolio
  6. 8.1.5 Adocia SAS Recent Developments
  7. 8.2 Neurimmune Holding AG
  8. 8.2.1 Neurimmune Holding AG Company Information
  9. 8.2.2 Neurimmune Holding AG Business Overview
  10. 8.2.3 Neurimmune Holding AG Islet Amyloid Polypeptide Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Neurimmune Holding AG Islet Amyloid Polypeptide Product Portfolio
  12. 8.2.5 Neurimmune Holding AG Recent Developments
  13. 8.3 Nordic Bioscience A/S
  14. 8.3.1 Nordic Bioscience A/S Company Information
  15. 8.3.2 Nordic Bioscience A/S Business Overview
  16. 8.3.3 Nordic Bioscience A/S Islet Amyloid Polypeptide Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Nordic Bioscience A/S Islet Amyloid Polypeptide Product Portfolio
  18. 8.3.5 Nordic Bioscience A/S Recent Developments
  19. 8.4 Prothena Corp Plc
  20. 8.4.1 Prothena Corp Plc Company Information
  21. 8.4.2 Prothena Corp Plc Business Overview
  22. 8.4.3 Prothena Corp Plc Islet Amyloid Polypeptide Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Prothena Corp Plc Islet Amyloid Polypeptide Product Portfolio
  24. 8.4.5 Prothena Corp Plc Recent Developments
  25. 8.5 reMYND NV
  26. 8.5.1 reMYND NV Company Information
  27. 8.5.2 reMYND NV Business Overview
  28. 8.5.3 reMYND NV Islet Amyloid Polypeptide Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 reMYND NV Islet Amyloid Polypeptide Product Portfolio
  30. 8.5.5 reMYND NV Recent Developments
  31. 8.6 Zealand Pharma AS
  32. 8.6.1 Zealand Pharma AS Company Information
  33. 8.6.2 Zealand Pharma AS Business Overview
  34. 8.6.3 Zealand Pharma AS Islet Amyloid Polypeptide Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Zealand Pharma AS Islet Amyloid Polypeptide Product Portfolio
  36. 8.6.5 Zealand Pharma AS Recent Developments
  37. 8.7 AstraZeneca Plc
  38. 8.7.1 AstraZeneca Plc Company Information
  39. 8.7.2 AstraZeneca Plc Business Overview
  40. 8.7.3 AstraZeneca Plc Islet Amyloid Polypeptide Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Plc Islet Amyloid Polypeptide Product Portfolio
  42. 8.7.5 AstraZeneca Plc Recent Developments
  43. 8.8 Eli Lilly and Co
  44. 8.8.1 Eli Lilly and Co Company Information
  45. 8.8.2 Eli Lilly and Co Business Overview
  46. 8.8.3 Eli Lilly and Co Islet Amyloid Polypeptide Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly and Co Islet Amyloid Polypeptide Product Portfolio
  48. 8.8.5 Eli Lilly and Co Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Islet Amyloid Polypeptide Value Chain Analysis
  2. 9.1.1 Islet Amyloid Polypeptide Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Islet Amyloid Polypeptide Sales Mode & Process
  6. 9.2 Islet Amyloid Polypeptide Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Islet Amyloid Polypeptide Distributors
  9. 9.2.3 Islet Amyloid Polypeptide Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst